Skip to main content


Page 1 of 5

  1. Capecitabine, a pro-drug of 5-fluorouracil, is commonly used in the treatment of breast and colorectal cancer. Its side effects, including nausea, vomiting, diarrhea, fatigue, loss of appetite, and bone marrow...

    Authors: Maciej Kabat, Roma Padalkar, Sara Hazaveh, Vladimir Joseph, David Feigenblum and Sean Sadikot
    Citation: Cardio-Oncology 2024 10:11
  2. Cardiotoxicity is one of the most common adverse events of the chemotherapy. Physical exercise was shown to be cardioprotective. We aim to estimate the efficacy and safety of exercise in cancer patients receiv...

    Authors: Ahmed Mazen Amin, Yehya Khlidj, Mohamed Abuelazm, Ahmed A. Ibrahim, Mohammad Tanashat, Muhammad Imran, Abubakar Nazir, Hosam Shaikhkhalil and Basel Abdelazeem
    Citation: Cardio-Oncology 2024 10:10
  3. The hematopoietic stem cell transplantation (HSCT) procedure is considered a cardiovascular burden. This is due to the potentially cardiotoxic cytostatic agents used before and the risks associated with peri-t...

    Authors: Bartosz Puła, Jarosław Kępski, Irena Misiewicz-Krzemińska and Sebastian Szmit
    Citation: Cardio-Oncology 2024 10:9
  4. This article provides an up-to-date overview of pericardial effusion in oncological practice and a guidance on its management. Furthermore, it addresses the question of when malignancy should be suspected in c...

    Authors: S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto and P. Ameri
    Citation: Cardio-Oncology 2024 10:8
  5. Thoracic radiotherapy may damage the myocardium and arteries, increasing cardiovascular disease (CVD) risk. Women with a high local breast cancer (BC) recurrence risk may receive an additional radiation boost ...

    Authors: Yvonne Koop, Femke Atsma, Marilot C.T. Batenburg, Hanneke Meijer, Femke van der Leij, Roxanne Gal, Sanne G.M. van Velzen, Ivana Išgum, Hester Vermeulen, Angela H.E.M. Maas, Saloua El Messaoudi and Helena M. Verkooijen
    Citation: Cardio-Oncology 2024 10:7
  6. Different breast cancer pharmacotherapy agents cause different forms of cardiovascular toxicity. We aim to assess if breast cancer pharmacotherapy trials approach cardiovascular safety in a targeted or general...

    Authors: Arsalan Hamid, Gregg C. Fonarow, Javed Butler and Michael E. Hall
    Citation: Cardio-Oncology 2024 10:6
  7. Authors: Jian Chu, Lillian Tung, Issam Atallah, Changli Wei, Melody Cobleigh, Ruta Rao, Steven B. Feinstein, Lydia Usha, Kathrin Banach, Jochen Reiser and Tochukwu M. Okwuosa
    Citation: Cardio-Oncology 2024 10:5

    The original article was published in Cardio-Oncology 2024 10:3

  8. Soluble urokinase plasminogen activator receptor is an inflammatory biomarker that may prognosticate cardiovascular outcomes. We sought to determine the associations between soluble urokinase plasminogen activ...

    Authors: Jian Chu, Lillian Tung, Issam Atallah, Changli Wei, Melody Cobleigh, Ruta Rao, Steven B. Feinstein, Lydia Usha, Kathrin Banach, Jochen Reiser and Tochukwu M. Okwuosa
    Citation: Cardio-Oncology 2024 10:3

    The Correction to this article has been published in Cardio-Oncology 2024 10:5

  9. Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs. Sodium-glucose cotransporter 2 in...

    Authors: Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, Yasmin Leshem, Or Bainhoren, Tammi Arbel Rubinstein, Maxim Perelman, Zach Rozenbaum, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Ido Wolf and Michal Laufer-Perl
    Citation: Cardio-Oncology 2024 10:2
  10. CT- coronary calcium score, is one of the most studied and widely available modalities in cardiovascular medicine. Coronary artery calcium score (CACS) is an established predictor of coronary artery disease. T...

    Authors: Sinal Patel, Francisco X. Franco, Malcolm McDonald, Carlos Rivera, Bernardo Perez-Villa, Patrick Collier, Rohit Moudgil, Neha Gupta and Diego B. Sadler
    Citation: Cardio-Oncology 2024 10:1
  11. Early identification of patients susceptible to chemotherapy-induced cardiotoxicity could lead to targeted treatment to reduce cardiac dysfunction. Rats treated with doxorubicin (DOX), a chemotherapeutic agent...

    Authors: Julia Matzenbacher dos Santos, Aby Joiakim, David A. Putt, Marielle Scherrer-Crosbie and Hyesook Kim
    Citation: Cardio-Oncology 2023 9:47
  12. Modern oncological therapies together with chemotherapy and radiotherapy have broadened the agents that can cause cardiac sequelae, which can manifest for pediatric oncology patients while on active treatment....

    Authors: Claudia Toro, Ben Felmingham, Mangesh Jhadav, David S. Celermajer, Andre La Gerche, John O’Sullivan, Sanjeev Kumar, Marion K. Mateos, Joy Fulbright, Dinisha Govender, Lane Collier, Michael Cheung, David D. Eisenstat, Peter W. Lange, Julian Ayer, David A. Elliott…
    Citation: Cardio-Oncology 2023 9:45
  13. Immune checkpoint inhibitors (ICI) and Tyrosine kinase inhibitors (TKI) are effective for several types of cancers, but they can have several cardiotoxicity sides effects. We present a case of TKI-ICI toxicity...

    Authors: Juan Del Cid Fratti, Vijayasree Paleru, Madhuri Bajaj and Chetan Bhardwaj
    Citation: Cardio-Oncology 2023 9:44

    The Correction to this article has been published in Cardio-Oncology 2024 10:4

  14. Asymptomatic childhood cancer survivors (CCS) frequently show decreased exercise performance. Poor exercise performance may indicate impaired future cardiovascular health.

    Authors: Takeshi Tsuda, Kimberly Davidow, Gina D’Aloisio and Joanne Quillen
    Citation: Cardio-Oncology 2023 9:42
  15. There is substantial evidence that systemic anticancer therapies and radiotherapy can increase the long-term risk of cardiovascular disease (CVD). Optimal management decisions for cancer patients therefore nee...

    Authors: Johanna Ramroth, Rebecca Shakir, Sarah C. Darby, David J. Cutter and Valerie Kuan
    Citation: Cardio-Oncology 2023 9:41
  16. The aim was to provide evidence about the prevalence, incidence, and risk factors of cardiac electrical abnormalities in childhood acute lymphoblastic leukemia (ALL) survivors.

    Authors: Émilie Bertrand, Maxime Caru, Audrey Harvey, Philippe Dodin, Vincent Jacquemet and Daniel Curnier
    Citation: Cardio-Oncology 2023 9:40
  17. Percutaneous left atrial appendage occlusion (LAAO) has been rapidly evolving since FDA’s approval in 2015 and has become more of a same-day-discharge procedure. Cancer patient with atrial fibrillation/flutter...

    Authors: Yaqi Zhang, Zhuoran Yang, Muhammad U. Almani, Raquel Soon-Shiong and Bolun Liu
    Citation: Cardio-Oncology 2023 9:39
  18. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorabl...

    Authors: Karishma Patel, Kristie Y. Hsu, Kevin Lou, Krishan Soni, Yoo Jin Lee, Claire K. Mulvey and Alan H. Baik
    Citation: Cardio-Oncology 2023 9:38

    The Correction to this article has been published in Cardio-Oncology 2023 9:43

  19. Millions of cancer survivors are at risk of cardiovascular diseases, a leading cause of morbidity and mortality. Tools to potentially facilitate implementation of cardiology guidelines, consensus recommendatio...

    Authors: Sherry-Ann Brown, Abdulaziz Hamid, Erin Pederson, Allen Hanna BS, Ragasnehith Maddula, Rachel Goodman, Morgan Lamberg, Pedro Caraballo, Peter Noseworthy, Opeoluwa Lukan, Gift Echefu, Generika Berman and Indrajit Choudhuri
    Citation: Cardio-Oncology 2023 9:37
  20. To determine the impact of acute SARS-CoV-2 infection on patient with concomitant active cancer and CVD.

    Authors: Brijesh Patel, Scott A. Chapman, Jake T. Neumann, Aayush Visaria, Oluwabunmi Ogungbe, Sijin Wen, Maryam Khodaverdi, Priyal Makwana, Jasvinder A. Singh and George Sokos
    Citation: Cardio-Oncology 2023 9:36
  21. Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiov...

    Authors: Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac and Ghazwa B. Korayem
    Citation: Cardio-Oncology 2023 9:35
  22. Immune checkpoint inhibitor (ICI) myocarditis is associated with significant mortality risk. Electrocardiogram (ECG) changes in ICI myocarditis have strong prognostic value. However the impact of complete hear...

    Authors: Michael P. O’Shea, Suganya Arunachalam Karikalan, Ali Yusuf, Timothy Barry, Eiad Habib, John O’Shea, Michael Killian, Eman Baqal, Srishti Nayak, Rajeev Masson, Joerg Hermann, Shimoli Shah, Chadi Ayoub and Hicham El Masry
    Citation: Cardio-Oncology 2023 9:34
  23. Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and rece...

    Authors: Andrew W. Hahn, Whittney Thoman, Efstratios Koutroumpakis, Amer Abdulla, Sumit K. Subudhi, Ana Aparicio, Karen Basen-Enngquist, Christopher J. Logothetis and Susan C. Gilchrist
    Citation: Cardio-Oncology 2023 9:33
  24. Baseline cardiovascular risk factors correction is recommended in all cancer patients undergoing potentially cardiotoxic therapies. Despite available guidelines, real-world data on dyslipidemia prevalence and ...

    Authors: Massimiliano Camilli, Irma Bisceglia, Maria Laura Canale, Fabio Maria Turazza, Leonardo De Luca, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva and Furio Colivicchi
    Citation: Cardio-Oncology 2023 9:32
  25. Patients treated for hematologic malignancy often experience reduced exercise capacity and increased fatigue; however whether this reduction is related to cardiac dysfunction or impairment of skeletal muscle o...

    Authors: Justin M. Canada, John McCarty, Jennifer H. Jordan, Cory R. Trankle, Kevin DeCamp, Josh D. West, Mary Ann Reynolds, Rachel Myers, Katey Sweat, Virginia McGhee, Ross Arena, Antonio Abbate and W. Gregory Hundley
    Citation: Cardio-Oncology 2023 9:31
  26. Cancer survival rates have been steadily improving in the adolescent and young adult (AYA) population, but survivors are at increased risk for cardiovascular disease (CVD). The cardiotoxic effects of anthracyc...

    Authors: Jeannette R. Wong-Siegel, Robert J. Hayashi, Randi Foraker and Joshua D. Mitchell
    Citation: Cardio-Oncology 2023 9:30
  27. Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022). Neuroendocrine tumors are rare with an ann...

    Authors: Aditi Sharma, Maria E. Fierro, Stella Pak, Keerthi Thallapureddy, Moyosore Awobajo, Dawn Hui and Prince Otchere
    Citation: Cardio-Oncology 2023 9:28
  28. 25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...

    Authors: Prince Otchere, Olusola Adekoya, Samuel B. Governor, Naveen Vuppuluri, Akruti Prabhakar, Stella Pak, Oduro Oppong-Nkrumah, Francis Cook, Rudy Bohinc and Gregory Aune
    Citation: Cardio-Oncology 2023 9:26
  29. Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.

    Authors: Matthew Dean, Min Jung Kim, Sharon Dimauro, Susan Tannenbaum, Garth Graham, Bruce T. Liang and Agnes S. Kim
    Citation: Cardio-Oncology 2023 9:23
  30. Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...

    Authors: N. Jacobi, S. Ortman, L. Buda and Daniel Duprez
    Citation: Cardio-Oncology 2023 9:21
  31. Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...

    Authors: Wafaa S. El-Sherbeny, Nesreen M. Sabry, Shaimaa B. El-Saied and Basma Elnagar
    Citation: Cardio-Oncology 2023 9:20
  32. Though the incidence of atrial fibrillation (AF) is increased in patients with cancer, the effectiveness of catheter ablation (CA) for AF in patients with cancer is not well studied.

    Authors: Sarju Ganatra, Sonu Abraham, Ashish Kumar, Rohan Parikh, Rushin Patel, Sumanth Khadke, Amudha Kumar, Victor Liu, Andrea Nathalie Rosas Diaz, Tomas G. Neilan, David Martin, Bruce Hook, Sourbha S. Dani, Aarti Asnani and Anju Nohria
    Citation: Cardio-Oncology 2023 9:19
  33. Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...

    Authors: Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand…
    Citation: Cardio-Oncology 2023 9:18
  34. Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography asso...

    Authors: Mônica M. C. Becker, Gustavo F. A. Arruda, Diego R. F. Berenguer, Roberto O. Buril, Daniela Cardinale and Simone C. S. Brandão
    Citation: Cardio-Oncology 2023 9:17
  35. Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mor...

    Authors: Khan O. Mohammad, Hanna Fanous, Sneha Vakamudi and Yan Liu
    Citation: Cardio-Oncology 2023 9:15
  36. Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well ...

    Authors: Jesus Jimenez, Nicolas Kostelecky, Joshua D. Mitchell, Kathleen W. Zhang, Chieh-Yu Lin, Daniel J. Lenihan and Kory J. Lavine
    Citation: Cardio-Oncology 2023 9:14
  37. Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor tre...

    Authors: Anthony F. Yu, Chau T. Dang, Justine Jorgensen, Chaya S. Moskowitz, Patricia DeFusco, Eric Oligino, Kevin C. Oeffinger, Jennifer E. Liu and Richard M. Steingart
    Citation: Cardio-Oncology 2023 9:13
  38. This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients.

    Authors: Yitao Zhang, Zicheng Huang, Sutian Hu, Jinhong Si, Shiyao Cheng, Zhichong Chen, Jiaojie Xue, Xue Lou, Huajing Peng, Zequan Li, Mao Ouyang, Xiang Gao and Weijie Zeng
    Citation: Cardio-Oncology 2023 9:12
  39. Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role...

    Authors: Tomohiro Kaneko, Sakiko Miyazaki, Azusa Kurita, Ryoko Morimoto, Shun Tsuchiya, Naoki Watanabe, Tomoiku Takaku, Norio Komatsu and Tohru Minamino
    Citation: Cardio-Oncology 2023 9:11
  40. Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...

    Authors: Ali Mir, Yasra Badi, Seif Bugazia, Anas Zakarya Nourelden, Ahmed Hashem Fathallah, Khaled Mohamed Ragab, Mohammed Alsillak, Sarah Makram Elsayed, Abdulrahman Ibrahim Hagrass, Sawyer Bawek, Mohamad Kalot and Zachary L. Brumberger
    Citation: Cardio-Oncology 2023 9:10

Annual Journal Metrics

  • 2022 Citation Impact
    3.3 - 2-year Impact Factor
    0.977 - SNIP (Source Normalized Impact per Paper)
    0.790 - SJR (SCImago Journal Rank)

    2022 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    130 days submission to accept (Median)

    2022 Usage 
    534 Altmetric mentions

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here